Biotechnology
4DMT is a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics designed to transform treatment paradigms and provide unprecedented benefits to patients. The company's lead product candidate 4D-150 is designed to provide multi-year sustained delivery of anti-VEGF therapies with a single intravitreal injection for treating blinding retinal vascular diseases, with its lead indication being wet age-related macular degeneration currently in Phase 3 development and a secondary indication in diabetic macular edema. The company's second product candidate 4D-710 is the first known genetic medicine to demonstrate successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis after aerosol delivery. 4DMT focuses on reducing treatment burden and advancing novel therapeutic approaches for patients with serious eye and genetic diseases.
Beta · Sourced from candidate reports
Be the first to share your experience with 4DMT.
Your reply helps other candidates know what to expect.
